ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1196

Analysis of Gene Expression Patterns in Rheumatoid  Arthritis (RA) Synovial Macrophages From Patients Undergoing Disease Flare

Karen L. Berg1, Adedayo Hanidu1, Jon Hill2, Xiaoyu Jiang1, Tom Freeman2, Jennifer Swantek1, Anna Yarlina3, George D. Kalliolias4, Lionel B. Ivashkiv5 and Gerald H. Nabozny1, 1Immunology and Inflammation, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 2Scientific Knowledge Discovery, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, 3Hospital for Special Surgery, New York, NY, 4Medicine, Hospital for Special Surgery, New York, NY, 5Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Inflammation, macrophages, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumamtoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Synovial macrophages play a key role in RA pathogenesis.  Their numbers are greatly increased in RA synovium, their phenotype is consistent with a pro-inflammatory function, and clinical data indicate all efficacious RA therapies lead to a significant reduction of this cell type in the diseased joint.  Studies probing global gene expression in RA synovial macrophages have been limited in scope.  We set out to further our understanding of synovial macrophage biology — both in RA and additional arthropathies — through gene expression profiling, gene mining and pathway analysis in synovial macrophages from patients undergoing disease flare. 

Methods: Synovial fluids were collected  from 10 RA patients in disease flare (treatments included oral DMARDs and/or biologics), and CD14+ cells  isolated by positive selection.  Control macrophage samples were generated from CD14+ peripheral blood monocytes from healthy donors, and differentiated with M-CSF.  Macrophages were also isolated from synovial fluid from patients with Psoriatic Arthritis and other arthropathies to allow for comparison of dysregulated genes and pathways across related diseases.  RNAs were isolated, processed, and transcriptional profiling of the samples was performed using Affymetrix arrays.  Statistical analysis was performed using principle component analysis (PCA) and upregulated genes defined as >2.0-fold increase in expression and an FDR p-value of <0.05.  Internal genesets from cytokine-stimulated macrophages, and M1 or  M2 polarized macrophages, were used as comparators to further characterize upregulated genes and pathways in RA macrophages.

Results: Approximately 1900 genes were significantly upregulated in RA synovial macrophages, and 70% demonstrated overlap with Psoriatic arthritis and other arthropathies.  Forty percent of RA-upregulated genes were upregulated in M1 polarized macrophages, vs. 7% in M2 macrophages.  Only 10% of RA-regulated genes were upregulated by chronic treatment of control macrophages with TNFa, indicating other factors impact gene expression to a greater extent in RA macrophages.  Gene Set Enrichment and Ingenuity Pathway Analysis indicated that several immunoregulatory pathways previously linked to RA pathogenesis were upregulated in RA macrophages (including CD40, and FcR), independent of treatment.  Interestingly, the LTb signaling pathway, which was highly upregulated in M1 macrophages was not significantly induced in RA macrophages indicating a unique inflammatory phenotype of these disease macrophages.

Conclusion: We performed a comprehensive study focused on identifying differentially regulated genes and pathways in synovial macrophages from patients with RA and related arthropathies.  These results suggest a unique inflammatory phenotype of RA macrophages and maintenance of key inflammatory pathways during flare that is independent of treatment.  These observations may shed light on novel intervention points for treatment of RA.


Disclosure:

K. L. Berg,

Boehringer Ingelheim,

3;

A. Hanidu,

Boehringer Ingelheim,

3;

J. Hill,

Boehringer Ingelheim,

3;

X. Jiang,

Boehringer Ingelheim,

3;

T. Freeman,

Boehringer Ingelheim,

3;

J. Swantek,

Boehringer Ingelheim,

3;

A. Yarlina,

Boehringer Ingelheim,

2;

G. D. Kalliolias,

Boehringer Ingelheim,

2;

L. B. Ivashkiv,

Boehringer Ingelheim,

2;

G. H. Nabozny,

Boehringer Ingelheim,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-gene-expression-patterns-in-rheumatoid-arthritis-ra-synovial-macrophages-from-patients-undergoing-disease-flare/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology